Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $17

COMPASS Pathways Plc Sponsored ADR

COMPASS Pathways Plc Sponsored ADR

CMPS

0.00

Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ: CMPS) with a Overweight and raises the price target from $16 to $17.